bcdiabetes.ca
Patient Care + Research + Clinical Trials

Dr. Tom Elliott MBBS, FRCPC
Medical Director

400 - 210 W Broadway
Vancouver, BC
V5Y 3W2 Canada

phone: 604.683.3734
fax: 604.628.3821
email: moa@bcdiabetes.ca

Type 1 diabetes clinical trials

Pre-Type 1 diabetes (stage 2, mildly elevated sugar, no symptoms, positive autoantibodies)

Baricade-delay RCT of baricitinib in stage 2 (pre-clinical) Type 1 diabetes age 1-36 years

Within 100 days of diagnosis of clinical symptomatic T1D (stage 3, on insulin)

Baricade-preserve: age 1-36 baricitinib in preservation of beta cells < 100 days

Teplizumab beta preserve age 17-35 at VGH under Drs. David Thompson & Ahsen Chaudhry

~~Recruitment completed 2026-Jan-13~~ ~~OBTAIN: age 12-21 years nanobody Rx starting 2026-Mar for preservation of beta cells <90 days of dx of Type 1~~
~~Recruitment completed 2024-Dec-04, study completed 2026-Feb-02, analysis underway:~~ ~~**UST1D2**: ustekinumab age 18-35 beta cell salvage & rejuvenation < 100 days of dx of Type 1~~. ~~58 BCDiabetes clients participated.~~

1+ year from diagnosis

~~Dual agonist (GLP-GIP) role in improving diabetic kidney disease: Canada not chosen for this study by the sponsor Roche pharmaceuticals~~

5+ years from diagnosis

Zucara: age 18-75 nocturnal hypoglycemia duration > 5 year (somatostatin antagonist)

Islet cell transplantation (typically > 5 years post diagnosis)

There is tremendous excitement around Sana Biotechnology's cell line - see this paper published 2025-Aug-4 (see https://bit.ly/4wsSgsY) by Per-Ola Carlsson's group in Uppsala, Sweden. The Carlson group showed functional survival of allogeneic human beta cells without immunosuppression transplanted into the forearm of a 42 year old man living with Type 1 for 37 years. Sana's cell line was genetically engineered to not incite an immune response and is blood group O Negative, meaning not only that anti-rejection drugs will not be required but blood type-matching of potential recipients will be unnecessary.

> Recruitment completed 2025-July-15: **Vertex 880** Islet Cell Transplant study at Vancouver General Hospital with Dr. Breay Paty as Principal Investigator. In this tremendously exciting study 10 of 12 subjects who received the Islet cell transplant required no insulin at the 12 month mark. Two BCDiabetes subjects have received this transplant (one in the original 12 who is insulin free after 3 years and another in Sept 2025, insulin requirements markedly reduced). Immunosuppression is required life-long. Note, the same study continues to recruit in Edmonton, contact the coordinator Saira Qureshi, Clinical Islet Transplant Program, University of Alberta, saira@ualberta.ca T 780-492-7942
> See published paper here

BCDiabetes is helping recruit subjects for a related **Vertex 880**, using the same cell line described in the successful study above, but for individuals with type 1 diabetes who have undergone a kidney transplant. For more information contact Dr. Breay Paty, Dr. Ahsen Chaudry or the study coordinator Levina Ira ph 604 875 4111 ex 62178

> ~~Study abandoned 2025-Mar-22 for lack of efficacy: **Vertex 264**: Islet cell transplant, age 18-65, T1 onset age < 40 yrs, duration of T1 > 5 years~~

Breakthrough T1D links for active clinical trials in T1D

Short URL = https://bit.ly/T1DCTs